<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191097</url>
  </required_header>
  <id_info>
    <org_study_id>4K/2013</org_study_id>
    <nct_id>NCT03191097</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.</brief_title>
  <official_title>Randomised Double-blind Placebo Controlled Multicenter Clinical Trial of Efficacy and Safety of Ingavirin® Capsules 30mg, in Daily Dose 60mg for the Treatment of Influenza and Other Acute Respiratory Viral Infections at Children 7-12 y.o.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valenta Pharm JSC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlant Clinical Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Valenta Pharm JSC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Ingavirin ® dosed 60 mg daily is effective
      and safe in the treatment of influenza and other acute respiratory viral infections in 7-12
      years old patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to resolution of fever</measure>
    <time_frame>7 ± 1 days</time_frame>
    <description>Time from the start of study treatment to resolution of fever ( t ≤ 36,9 ºС)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of intoxication symptoms</measure>
    <time_frame>7 ± 1 days</time_frame>
    <description>Time from the start of study treatment to resolution of all intoxication symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of catarrhal symptoms</measure>
    <time_frame>7 ± 1 days</time_frame>
    <description>Time from the start of study treatment to resolution of all catarrhal symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of subjects with resolution of fever</measure>
    <time_frame>7 ± 1</time_frame>
    <description>Proportion of subjects with resolution of fever by 1st, 2nd, 3rd, 4th and 5th days of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects with development of complications of Influenza or other acute respiratory viral infection</measure>
    <time_frame>21 ± 1</time_frame>
    <description>Proportion of subjects who developed complications during treatment period (7 ± 1 days) and follow-up period (21 ± 1 days)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Influenza, Human</condition>
  <condition>Acute Respiratory Infection</condition>
  <condition>Viral Infection</condition>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Ingavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingavirin</intervention_name>
    <description>Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.</description>
    <arm_group_label>Ingavirin</arm_group_label>
    <other_name>Imidazolyl ethanamide pentandioic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo, capsules daily for 5 days.</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The informed consent form signed by the patient's parent/adoptive parent to
             participate in the clinical study

          -  Male and female patients aged 7-12

          -  Patients with moderate course of influenza or other acute respiratory viral infections
             (AVRI)

          -  Patients with clinically diagnosed influenza or other ARVI based on the body
             temperature &gt; 37,5 ° C, not less than 1 of the following other symptoms of
             intoxication and not less than 1 of the following of catarrhal symptoms:

          -  Intoxication symptoms: headache, malaise, myalgia, pain in the eyeballs;

          -  Catarrhal symptoms: sore throat, rhinorrhea, cough, nasal congestion

          -  Uncomplicated course of influenza and other ARVI

          -  Interval between onset of symptoms and enrollment to the study of not more than 36
             hours

        Exclusion Criteria:

          -  Complicated course of influenza and other acute respiratory viral infections

          -  Treatment with antiviral drugs (antivirals, interferons and interferon inducers),
             drugs with immunomodulatory effects or antibiotics with systemic and local action
             within 7 days prior to the screening visit

          -  Severe influenza or other ARVI with symptoms of cardiovascular disease, and other
             symptoms of infectious-toxic shock, and meningoencephalitic syndromes

          -  Signs of primary viral pneumonia development (presence of two or more of the following
             symptoms): shortness of breath, chest pain when coughing, systemic cyanosis, dullness
             of percussion sound at symmetrical assessment of the upper and lower parts of the
             lungs

          -  Infectious diseases within the last week prior to enrollment

          -  &quot;RRI children&quot; (incidence of ARVI within the last 12 months is 6 times or more)

          -  Asthma history

          -  History of increased seizure activity

          -  Severe decompensated or unstable medical or psychiatric conditions (any diseases or
             conditions that threaten the life of the patient or worsen the patient's prognosis and
             also make it impossible to conduct a clinical study in the patient).

          -  Cancer, HIV infection, tuberculosis, including those in history

          -  Hypersensitivity to imidazolyl ethanamide pentandioic acid and/or excipients of
             Ingavirin product

          -  Diabetes, lactose intolerance, lactase deficiency, glucose-galactose malabsorption,
             deficiency of sucrase/isomaltase, fructose intolerance, hereditary glucose
             malabsorption, deficiency of glucose-6-phosphate dehydrogenase

          -  Participation of the patient in any other clinical trial within the last 90 days prior
             to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekaterina Zakharova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Valenta Pharm JSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GBOU VPO &quot;Kazan State Medical University&quot; of Ministry of Health of Russian Federation</name>
      <address>
        <city>Kazan'</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk State Medical University named after Prof. V.F.Voino-Yasenetsky</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.M. Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novosibirsk State Medical University</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Pediatric Outpatient Clinic number 5</name>
      <address>
        <city>Perm</city>
        <zip>614066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-na-Donu</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics outpatient clinic number 4 of Rostov-na-Donu</name>
      <address>
        <city>Rostov-na-Donu</city>
        <zip>344065</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogarev Mordovia State University</name>
      <address>
        <city>Saransk</city>
        <zip>430005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University named after V. I. Razumovsky</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBOU VPO &quot;Yaroslavl State Medical University&quot; of Ministry of Health of Russian Federation</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrician City Hospital number 11</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>62028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <results_reference>
    <citation>I.M. Farber, N.A. Geppe, D.V. Reikhart, V.E. Nebolsin, V.S. Arnautov, A.A. Globenko. Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes. Ros Vestn Perinatol Pediat 2016; 2:115-120. Russian.</citation>
  </results_reference>
  <results_reference>
    <citation>N.A. Geppe, E.D. Teplyakova, A.A. Shuldyakov, E.P. Lyapina, O.A. Perminova, G.P. Martynova, I.G. Sitnikov, V.A. Anohin, G.R. Fatkullina, V.V. Romanenko, A.A. Savisko, E.G. Kondyurina, L.A. Balykova. Innovations in pediatrics: the optimal clinical effect In acute respiratory viral infections treatment In children with complex action drug. Pediatry 2016, 2(95), 97-103. Russian.</citation>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Common Cold</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

